{
  "symbol": "ABBV",
  "year": 2023,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2594,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.052
  },
  "top_positive": [
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 United States $ 9,201 $ 10,348 (11.1) % (11.1) % International 3,024 3,190 (5.2) % 0.9 % Net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % 2023 Form 10-Q | 26 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Immunology Humira United States $ 2,948 $ 3,993 (26.1) % (26.1) % International 593 743 (20.3) % (14.8) % Total $ 3,541 $ 4,736 (25.2) % (24.3) % Skyrizi United States $ 1,139 $ 781 45.9 % 45.9 % International 221 159 38.5 % 47.7 % Total $ 1,360 $ 940 44.7 % 46.3 % Rinvoq United States $ 449 $ 311 44.4 % 44.4 % International 237 154 53.7 % 64.9 % Total $ 686 $ 465 47.5 % 51.2 % Hematologic Oncology Imbruvica United States $ 638 $ 874 (27.0) % (27.0) % Collaboration revenues 240 299 (19.7) % (19.7) % Total $ 878 $ 1,173 (25.2) % (25.2) % Venclexta United States $ 265 $ 228 15.7 % 15.7 % International 273 245 11.8 % 19.2 % Total $ 538 $ 473 13.7 % 17.5 % Aesthetics Botox Cosmetic United States $ 409 $ 413 (0.7) % (0.7) % International 250 228 9.4 % 17.5 % Total $ 659 $ 641 2.9 % 5.8 % Juvederm Collection United States $ 122 $ 148 (17.9) % (17.9) % International 233 262 (10.9) % (1.4) % Total $ 355 $ 410 (13.4) % (7.4) % Other Aesthetics United States $ 246 $ 285 (13.6) % (13.6) % International 40 38 3.6 % 12.7 % Total $ 286 $ 323 (11.5) % (10.4) % Neuroscience Botox Therapeutic United States $ 587 $ 500 17.5 % 17.5 % International 132 114 15.5 % 24.2 % Total $ 719 $ 614 17.1 % 18.7 % Vraylar United States $ 560 $ 427 31.2 % 31.2 % International 1 \u2014 n/m n/m Total $ 561 $ 427 31.3 % 31.3 % Duodopa United States $ 25 $ 24 6.5 % 6.5 % International 93 97 (4.3) % 1.7 % Total $ 118 $ 121 (2.2) % 2.6 % Ubrelvy United States $ 150 $ 138 9.0 % 9.0 % International 2 \u2014 n/m n/m Total $ 152 $ 138 10.0 % 10.0 % Qulipta United States $ 66 $ 11 >100.0 % >100.0 % Other Neuroscience United States $ 75 $ 173 (56.7) % (56.7) % International 4 4 6.9 % 12.6 % Total $ 79 $ 177 (55.2) % (55.1) % 2023 Form 10-Q | 27 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Eye Care Ozurdex United States $ 39 $ 33 16.1 % 16.1 % International 76 74 3.2 % 10.3 % Total $ 115 $ 107 7.3 % 12.2 % Lumigan/Ganfort United States $ 63 $ 67 (6.8) % (6.8) % International 67 73 (7.2) % (2.7) % Total $ 130 $ 140 (7.0) % (4.7) % Alphagan/Combigan United States $ 28 $ 70 (59.4) % (59.4) % International 43 37 16.9 % 24.2 % Total $ 71 $ 107 (33.3) % (30.8) % Restasis United States $ 79 $ 235 (66.5) % (66.5) % International 13 11 20.4 % 25.1 % Total $ 92 $ 246 (62.8) % (62.6) % Other Eye Care United States $ 110 $ 91 22.9 % 22.9 % International 90 80 10.3 % 16.3 % Total $ 200 $ 171 16.9 % 19.8 % Other Key Products Mavyret United States $ 171 $ 169 1.2 % 1.2 % International 193 211 (8.1) % (1.8) % Total $ 364 $ 380 (4.0) % (0.5) % Creon United States $ 305 $ 287 6.3 % 6.3 % Linzess/Constella United States $ \n.S.",
      "score": 0.9964
    },
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 United States $ 9,201 $ 10,348 (11.1) % (11.1) % International 3,024 3,190 (5.2) % 0.9 % Net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % 2023 Form 10-Q | 26 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Immunology Humira United States $ 2,948 $ 3,993 (26.1) % (26.1) % International 593 743 (20.3) % (14.8) % Total $ 3,541 $ 4,736 (25.2) % (24.3) % Skyrizi United States $ 1,139 $ 781 45.9 % 45.9 % International 221 159 38.5 % 47.7 % Total $ 1,360 $ 940 44.7 % 46.3 % Rinvoq United States $ 449 $ 311 44.4 % 44.4 % International 237 154 53.7 % 64.9 % Total $ 686 $ 465 47.5 % 51.2 % Hematologic Oncology Imbruvica United States $ 638 $ 874 (27.0) % (27.0) % Collaboration revenues 240 299 (19.7) % (19.7) % Total $ 878 $ 1,173 (25.2) % (25.2) % Venclexta United States $ 265 $ 228 15.7 % 15.7 % International 273 245 11.8 % 19.2 % Total $ 538 $ 473 13.7 % 17.5 % Aesthetics Botox Cosmetic United States $ 409 $ 413 (0.7) % (0.7) % International 250 228 9.4 % 17.5 % Total $ 659 $ 641 2.9 % 5.8 % Juvederm Collection United States $ 122 $ 148 (17.9) % (17.9) % International 233 262 (10.9) % (1.4) % Total $ 355 $ 410 (13.4) % (7.4) % Other Aesthetics United States $ 246 $ 285 (13.6) % (13.6) % International 40 38 3.6 % 12.7 % Total $ 286 $ 323 (11.5) % (10.4) % Neuroscience Botox Therapeutic United States $ 587 $ 500 17.5 % 17.5 % International 132 114 15.5 % 24.2 % Total $ 719 $ 614 17.1 % 18.7 % Vraylar United States $ 560 $ 427 31.2 % 31.2 % International 1 \u2014 n/m n/m Total $ 561 $ 427 31.3 % 31.3 % Duodopa United States $ 25 $ 24 6.5 % 6.5 % International 93 97 (4.3) % 1.7 % Total $ 118 $ 121 (2.2) % 2.6 % Ubrelvy United States $ 150 $ 138 9.0 % 9.0 % International 2 \u2014 n/m n/m Total $ 152 $ 138 10.0 % 10.0 % Qulipta United States $ 66 $ 11 >100.0 % >100.0 % Other Neuroscience United States $ 75 $ 173 (56.7) % (56.7) % International 4 4 6.9 % 12.6 % Total $ 79 $ 177 (55.2) % (55.1) % 2023 Form 10-Q | 27 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Eye Care Ozurdex United States $ 39 $ 33 16.1 % 16.1 % International 76 74 3.2 % 10.3 % Total $ 115 $ 107 7.3 % 12.2 % Lumigan/Ganfort United States $ 63 $ 67 (6.8) % (6.8) % International 67 73 (7.2) % (2.7) % Total $ 130 $ 140 (7.0) % (4.7) % Alphagan/Combigan United States $ 28 $ 70 (59.4) % (59.4) % International 43 37 16.9 % 24.2 % Total $ 71 $ 107 (33.3) % (30.8) % Restasis United States $ 79 $ 235 (66.5) % (66.5) % International 13 11 20.4 % 25.1 % Total $ 92 $ 246 (62.8) % (62.6) % Other Eye Care United States $ 110 $ 91 22.9 % 22.9 % International 90 80 10.3 % 16.3 % Total $ 200 $ 171 16.9 % 19.8 % Other Key Products Mavyret United States $ 171 $ 169 1.2 % 1.2 % International 193 211 (8.1) % (1.8) % Total $ 364 $ 380 (4.0) % (0.5) % Creon United States $ 305 $ 287 6.3 % 6.3 % Linzess/Constella United States $ 251 $ 233 7.7 % 7.7 % International 8 7 11.9 % 17.8 % Total $ 259 $ 240 7.8 % 8.0 % All other $ 691 $ 1,211 (43.1) % (42.2) % Total net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.9963
    },
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 United States $ 9,201 $ 10,348 (11.1) % (11.1) % International 3,024 3,190 (5.2) % 0.9 % Net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % 2023 Form 10-Q | 26 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Immunology Humira United States $ 2,948 $ 3,993 (26.1) % (26.1) % International 593 743 (20.3) % (14.8) % Total $ 3,541 $ 4,736 (25.2) % (24.3) % Skyrizi United States $ 1,139 $ 781 45.9 % 45.9 % International 221 159 38.5 % 47.7 % Total $ 1,360 $ 940 44.7 % 46.3 % Rinvoq United States $ 449 $ 311 44.4 % 44.4 % International 237 154 53.7 % 64.9 % Total $ 686 $ 465 47.5 % 51.2 % Hematologic Oncology Imbruvica United States $ 638 $ 874 (27.0) % (27.0) % Collaboration revenues 240 299 (19.7) % (19.7) % Total $ 878 $ 1,173 (25.2) % (25.2) % Venclexta United States $ 265 $ 228 15.7 % 15.7 % International 273 245 11.8 % 19.2 % Total $ 538 $ 473 13.7 % 17.5 % Aesthetics Botox Cosmetic United States $ 409 $ 413 (0.7) % (0.7) % International 250 228 9.4 % 17.5 % Total $ 659 $ 641 2.9 % 5.8 % Juvederm Collection United States $ 122 $ 148 (17.9) % (17.9) % International 233 262 (10.9) % (1.4) % Total $ 355 $ 410 (13.4) % (7.4) % Other Aesthetics United States $ 246 $ 285 (13.6) % (13.6) % International 40 38 3.6 % 12.7 % Total $ 286 $ 323 (11.5) % (10.4) % Neuroscience Botox Therapeutic United States $ 587 $ 500 17.5 % 17.5 % International 132 114 15.5 % 24.2 % Total $ 719 $ 614 17.1 % 18.7 % Vraylar United States $ 560 $ 427 31.2 % 31.2 % International 1 \u2014 n/m n/m Total $ 561 $ 427 31.3 % 31.3 % Duodopa United States $ 25 $ 24 6.5 % 6.5 % International 93 97 (4.3) % 1.7 % Total $ 118 $ 121 (2.2) % 2.6 % Ubrelvy United States $ 150 $ 138 9.0 % 9.0 % International 2 \u2014 n/m n/m Total $ 152 $ 138 10.0 % 10.0 % Qulipta United States $ 66 $ 11 >100.0 % >100.0 % Other Neuroscience United States $ 75 $ 173 (56.7) % (56.7) % International 4 4 6.9 % 12.6 % Total $ 79 $ 177 (55.2) % (55.1) % 2023 Form 10-Q | 27 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Eye Care Ozurdex United States $ 39 $ 33 16.1 % 16.1 % International 76 74 3.2 % 10.3 % Total $ 115 $ 107 7.3 % 12.2 % Lumigan/Ganfort United States $ 63 $ 67 (6.8) % (6.8) % International 67 73 (7.2) % (2.7) % Total $ 130 $ 140 (7.0) % (4.7) % Alphagan/Combigan United States $ 28 $ 70 (59.4) % (59.4) % International 43 37 16.9 % 24.2 % Total $ 71 $ 107 (33.3) % (30.8) % Resta\nthe change in fair value of contingent consideration liabilities; (ii) $1.6\u00a0billion related to the amortization of intangible assets; (iii) $629 million related to intangible asset impairment; and (iv) $55\u00a0million of acquisition and integration expenses.",
      "score": 0.9952
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.",
      "score": -0.7506
    },
    {
      "sent": "AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud.",
      "score": -0.7269
    }
  ],
  "forward_snippets": [
    "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also reducing debt.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "AbbVie\u2019s pipeline currently includes over 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.",
    "For a more comprehensive discussion of AbbVie\u2019s products and pipeline, see the company\u2019s Annual Report on Form\u00a010-K for the year ended December 31, 2022.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands."
  ],
  "curated_text": "Symbol: ABBV. Year: 2023. Period: Q3. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 United States $ 9,201 $ 10,348 (11.1) % (11.1) % International 3,024 3,190 (5.2) % 0.9 % Net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % 2023 Form 10-Q | 26 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Immunology Humira United States $ 2,948 $ 3,993 (26.1) % (26.1) % International 593 743 (20.3) % (14.8) % Total $ 3,541 $ 4,736 (25.2) % (24.3) % Skyrizi United States $ 1,139 $ 781 45.9 % 45.9 % International 221 159 38.5 % 47.7 % Total $ 1,360 $ 940 44.7 % 46.3 % Rinvoq United States $ 449 $ 311 44.4 % 44.4 % International 237 154 53.7 % 64.9 % Total $ 686 $ 465 47.5 % 51.2 % Hematologic Oncology Imbruvica United States $ 638 $ 874 (27.0) % (27.0) % Collaboration revenues 240 299 (19.7) % (19.7) % Total $ 878 $ 1,173 (25.2) % (25.2) % Venclexta United States $ 265 $ 228 15.7 % 15.7 % International 273 245 11.8 % 19.2 % Total $ 538 $ 473 13.7 % 17.5 % Aesthetics Botox Cosmetic United States $ 409 $ 413 (0.7) % (0.7) % International 250 228 9.4 % 17.5 % Total $ 659 $ 641 2.9 % 5.8 % Juvederm Collection United States $ 122 $ 148 (17.9) % (17.9) % International 233 262 (10.9) % (1.4) % Total $ 355 $ 410 (13.4) % (7.4) % Other Aesthetics United States $ 246 $ 285 (13.6) % (13.6) % International 40 38 3.6 % 12.7 % Total $ 286 $ 323 (11.5) % (10.4) % Neuroscience Botox Therapeutic United States $ 587 $ 500 17.5 % 17.5 % International 132 114 15.5 % 24.2 % Total $ 719 $ 614 17.1 % 18.7 % Vraylar United States $ 560 $ 427 31.2 % 31.2 % International 1 \u2014 n/m n/m Total $ 561 $ 427 31.3 % 31.3 % Duodopa United States $ 25 $ 24 6.5 % 6.5 % International 93 97 (4.3) % 1.7 % Total $ 118 $ 121 (2.2) % 2.6 % Ubrelvy United States $ 150 $ 138 9.0 % 9.0 % International 2 \u2014 n/m n/m Total $ 152 $ 138 10.0 % 10.0 % Qulipta United States $ 66 $ 11 >100.0 % >100.0 % Other Neuroscience United States $ 75 $ 173 (56.7) % (56.7) % International 4 4 6.9 % 12.6 % Total $ 79 $ 177 (55.2) % (55.1) % 2023 Form 10-Q | 27 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Eye Care Ozurdex United States $ 39 $ 33 16.1 % 16.1 % International 76 74 3.2 % 10.3 % Total $ 115 $ 107 7.3 % 12.2 % Lumigan/Ganfort United States $ 63 $ 67 (6.8) % (6.8) % International 67 73 (7.2) % (2.7) % Total $ 130 $ 140 (7.0) % (4.7) % Alphagan/Combigan United States $ 28 $ 70 (59.4) % (59.4) % International 43 37 16.9 % 24.2 % Total $ 71 $ 107 (33.3) % (30.8) % Restasis United States $ 79 $ 235 (66.5) % (66.5) % International 13 11 20.4 % 25.1 % Total $ 92 $ 246 (62.8) % (62.6) % Other Eye Care United States $ 110 $ 91 22.9 % 22.9 % International 90 80 10.3 % 16.3 % Total $ 200 $ 171 16.9 % 19.8 % Other Key Products Mavyret United States $ 171 $ 169 1.2 % 1.2 % International 193 211 (8.1) % (1.8) % Total $ 364 $ 380 (4.0) % (0.5) % Creon United States $ 305 $ 287 6.3 % 6.3 % Linzess/Constella United States $ \n.S. Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 United States $ 9,201 $ 10,348 (11.1) % (11.1) % International 3,024 3,190 (5.2) % 0.9 % Net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % 2023 Form 10-Q | 26 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Immunology Humira United States $ 2,948 $ 3,993 (26.1) % (26.1) % International 593 743 (20.3) % (14.8) % Total $ 3,541 $ 4,736 (25.2) % (24.3) % Skyrizi United States $ 1,139 $ 781 45.9 % 45.9 % International 221 159 38.5 % 47.7 % Total $ 1,360 $ 940 44.7 % 46.3 % Rinvoq United States $ 449 $ 311 44.4 % 44.4 % International 237 154 53.7 % 64.9 % Total $ 686 $ 465 47.5 % 51.2 % Hematologic Oncology Imbruvica United States $ 638 $ 874 (27.0) % (27.0) % Collaboration revenues 240 299 (19.7) % (19.7) % Total $ 878 $ 1,173 (25.2) % (25.2) % Venclexta United States $ 265 $ 228 15.7 % 15.7 % International 273 245 11.8 % 19.2 % Total $ 538 $ 473 13.7 % 17.5 % Aesthetics Botox Cosmetic United States $ 409 $ 413 (0.7) % (0.7) % International 250 228 9.4 % 17.5 % Total $ 659 $ 641 2.9 % 5.8 % Juvederm Collection United States $ 122 $ 148 (17.9) % (17.9) % International 233 262 (10.9) % (1.4) % Total $ 355 $ 410 (13.4) % (7.4) % Other Aesthetics United States $ 246 $ 285 (13.6) % (13.6) % International 40 38 3.6 % 12.7 % Total $ 286 $ 323 (11.5) % (10.4) % Neuroscience Botox Therapeutic United States $ 587 $ 500 17.5 % 17.5 % International 132 114 15.5 % 24.2 % Total $ 719 $ 614 17.1 % 18.7 % Vraylar United States $ 560 $ 427 31.2 % 31.2 % International 1 \u2014 n/m n/m Total $ 561 $ 427 31.3 % 31.3 % Duodopa United States $ 25 $ 24 6.5 % 6.5 % International 93 97 (4.3) % 1.7 % Total $ 118 $ 121 (2.2) % 2.6 % Ubrelvy United States $ 150 $ 138 9.0 % 9.0 % International 2 \u2014 n/m n/m Total $ 152 $ 138 10.0 % 10.0 % Qulipta United States $ 66 $ 11 >100.0 % >100.0 % Other Neuroscience United States $ 75 $ 173 (56.7) % (56.7) % International 4 4 6.9 % 12.6 % Total $ 79 $ 177 (55.2) % (55.1) % 2023 Form 10-Q | 27 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Eye Care Ozurdex United States $ 39 $ 33 16.1 % 16.1 % International 76 74 3.2 % 10.3 % Total $ 115 $ 107 7.3 % 12.2 % Lumigan/Ganfort United States $ 63 $ 67 (6.8) % (6.8) % International 67 73 (7.2) % (2.7) % Total $ 130 $ 140 (7.0) % (4.7) % Alphagan/Combigan United States $ 28 $ 70 (59.4) % (59.4) % International 43 37 16.9 % 24.2 % Total $ 71 $ 107 (33.3) % (30.8) % Restasis United States $ 79 $ 235 (66.5) % (66.5) % International 13 11 20.4 % 25.1 % Total $ 92 $ 246 (62.8) % (62.6) % Other Eye Care United States $ 110 $ 91 22.9 % 22.9 % International 90 80 10.3 % 16.3 % Total $ 200 $ 171 16.9 % 19.8 % Other Key Products Mavyret United States $ 171 $ 169 1.2 % 1.2 % International 193 211 (8.1) % (1.8) % Total $ 364 $ 380 (4.0) % (0.5) % Creon United States $ 305 $ 287 6.3 % 6.3 % Linzess/Constella United States $ 251 $ 233 7.7 % 7.7 % International 8 7 11.9 % 17.8 % Total $ 259 $ 240 7.8 % 8.0 % All other $ 691 $ 1,211 (43.1) % (42.2) % Total net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis. Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 United States $ 9,201 $ 10,348 (11.1) % (11.1) % International 3,024 3,190 (5.2) % 0.9 % Net revenues $ 12,225 $ 13,538 (9.7) % (8.3) % 2023 Form 10-Q | 26 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Immunology Humira United States $ 2,948 $ 3,993 (26.1) % (26.1) % International 593 743 (20.3) % (14.8) % Total $ 3,541 $ 4,736 (25.2) % (24.3) % Skyrizi United States $ 1,139 $ 781 45.9 % 45.9 % International 221 159 38.5 % 47.7 % Total $ 1,360 $ 940 44.7 % 46.3 % Rinvoq United States $ 449 $ 311 44.4 % 44.4 % International 237 154 53.7 % 64.9 % Total $ 686 $ 465 47.5 % 51.2 % Hematologic Oncology Imbruvica United States $ 638 $ 874 (27.0) % (27.0) % Collaboration revenues 240 299 (19.7) % (19.7) % Total $ 878 $ 1,173 (25.2) % (25.2) % Venclexta United States $ 265 $ 228 15.7 % 15.7 % International 273 245 11.8 % 19.2 % Total $ 538 $ 473 13.7 % 17.5 % Aesthetics Botox Cosmetic United States $ 409 $ 413 (0.7) % (0.7) % International 250 228 9.4 % 17.5 % Total $ 659 $ 641 2.9 % 5.8 % Juvederm Collection United States $ 122 $ 148 (17.9) % (17.9) % International 233 262 (10.9) % (1.4) % Total $ 355 $ 410 (13.4) % (7.4) % Other Aesthetics United States $ 246 $ 285 (13.6) % (13.6) % International 40 38 3.6 % 12.7 % Total $ 286 $ 323 (11.5) % (10.4) % Neuroscience Botox Therapeutic United States $ 587 $ 500 17.5 % 17.5 % International 132 114 15.5 % 24.2 % Total $ 719 $ 614 17.1 % 18.7 % Vraylar United States $ 560 $ 427 31.2 % 31.2 % International 1 \u2014 n/m n/m Total $ 561 $ 427 31.3 % 31.3 % Duodopa United States $ 25 $ 24 6.5 % 6.5 % International 93 97 (4.3) % 1.7 % Total $ 118 $ 121 (2.2) % 2.6 % Ubrelvy United States $ 150 $ 138 9.0 % 9.0 % International 2 \u2014 n/m n/m Total $ 152 $ 138 10.0 % 10.0 % Qulipta United States $ 66 $ 11 >100.0 % >100.0 % Other Neuroscience United States $ 75 $ 173 (56.7) % (56.7) % International 4 4 6.9 % 12.6 % Total $ 79 $ 177 (55.2) % (55.1) % 2023 Form 10-Q | 27 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 Eye Care Ozurdex United States $ 39 $ 33 16.1 % 16.1 % International 76 74 3.2 % 10.3 % Total $ 115 $ 107 7.3 % 12.2 % Lumigan/Ganfort United States $ 63 $ 67 (6.8) % (6.8) % International 67 73 (7.2) % (2.7) % Total $ 130 $ 140 (7.0) % (4.7) % Alphagan/Combigan United States $ 28 $ 70 (59.4) % (59.4) % International 43 37 16.9 % 24.2 % Total $ 71 $ 107 (33.3) % (30.8) % Resta\nthe change in fair value of contingent consideration liabilities; (ii) $1.6\u00a0billion related to the amortization of intangible assets; (iii) $629 million related to intangible asset impairment; and (iv) $55\u00a0million of acquisition and integration expenses. Top negative sentences: Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. Forward-looking snippets: AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also reducing debt. Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands. AbbVie\u2019s pipeline currently includes over 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care. For a more comprehensive discussion of AbbVie\u2019s products and pipeline, see the company\u2019s Annual Report on Form\u00a010-K for the year ended December 31, 2022. Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands."
}